Skip to main content

Search Videos and More

Showing 13 - 24 of 31 results

Previous| 1 | 2 | 3 |Next

Are there specific clinical phenotypes that are uniquely responsive to inhibition of type 2 cytokine-signaling proteins, or do patients across the moderate-to-severe spectrum of AD seem to respond with predictable success?

Are there specific clinical phenotypes that are uniquely responsive to inhibition of type 2 cytokine-signaling proteins, or do patients across the moderate-to-severe spectrum of AD seem to respond with predictable success?

Why is it important to parse out clinical phenotypes among pediatric and adult populations with atopic dermatitis? What is the importance of identifying clinical signatures and how can this impact therapeutic response and tolerability to therapies?

Why is it important to parse out clinical phenotypes among pediatric and adult populations with atopic dermatitis? What is the importance of identifying clinical signatures and how can this impact therapeutic response and tolerability to therapies?

In light of the significant unmet need for AD treatment in children between the ages of 2 and 12, and even younger what do the most recent clinical trials show about the safety and efficacy of dupilumab in these young age groups?

In light of the significant unmet need for AD treatment in children between the ages of 2 and 12, and even younger what do the most recent clinical trials show about the safety and efficacy of dupilumab in these young age groups?

Can you review the current evidentiary basis for the deployment of dupilumab in pediatric and adolescent age groups, and how clinical outcomes, time to resolution, and dosing consideration compare to results reported in the original trials in adults?

Can you review the current evidentiary basis for the deployment of dupilumab in pediatric and adolescent age groups, and how clinical outcomes, time to resolution, and dosing consideration compare to results reported in the original trials in adults?

In the dupilumab trials, do patients treated with this agent respond predictably in terms of amelioration of specific symptoms—itch, redness, appearance—and how long does it take to see treatment response?

In the dupilumab trials, do patients treated with this agent respond predictably in terms of amelioration of specific symptoms—itch, redness, appearance—and how long does it take to see treatment response?

Many dermatologists—and patients—are asking whether, during the Covid-19 pandemic, biologics such as dupilumab should be stopped in patients with AD? What are your recommendations?

Many dermatologists—and patients—are asking whether, during the Covid-19 pandemic, biologics such as dupilumab should be stopped in patients with AD? What are your recommendations?

Given the spectrum of therapeutic modalities for moderate-to-severe AD, can you provide a “therapeutic ladder” for how treatments, from corticosteroids to immunologically-based therapies should be sequenced in pediatric and adolescent patients?

Given the spectrum of therapeutic modalities for moderate-to-severe AD, can you provide a “therapeutic ladder” for how treatments, from corticosteroids to immunologically-based therapies should be sequenced in pediatric and adolescent patients?

Now that dupilumab has received formal FDA approval for use in the 6-11 age group, can you share what your clinical experience has been using this biologic in the pre-adolescent, pediatric age group?

Now that dupilumab has received formal FDA approval for use in the 6-11 age group, can you share what your clinical experience has been using this biologic in the pre-adolescent, pediatric age group?

With respect to dupilumab, what is the mechanistic relevance of targeting type 2 cytokine signaling systems—IL-4 and IL-13—and how does this translate into clinical effectiveness observed in clinical trials?

With respect to dupilumab, what is the mechanistic relevance of targeting type 2 cytokine signaling systems—IL-4 and IL-13—and how does this translate into clinical effectiveness observed in clinical trials?

The heterogeneity of atopic dermatitis in pediatric, adolescent, and adult populations is a critical feature of AD and, through precise identification of phenotypes and endotypes, can provide a therapy roadmap. Why is this important?

The heterogeneity of atopic dermatitis in pediatric, adolescent, and adult populations is a critical feature of AD and, through precise identification of phenotypes and endotypes, can provide a therapy roadmap. Why is this important?

What is the rationale and evidence that supports prompt, intensive, severity-of-disease-appropriate management of moderate-to-severe AD in the pediatric and adolescent age group?

What is the rationale and evidence that supports prompt, intensive, severity-of-disease-appropriate management of moderate-to-severe AD in the pediatric and adolescent age group?

Can you give us a sense of the disease burden—physiological, symptomatic, and psychological—associated with atopic dermatitis (AD) in children and adolescent patients; and to what degree is it, or can it be, truly debilitating?

Can you give us a sense of the disease burden—physiological, symptomatic, and psychological—associated with atopic dermatitis (AD) in children and adolescent patients; and to what degree is it, or can it be, truly debilitating?

Showing 13 - 24 of 31 results

Previous| 1 | 2 | 3 |Next